Aarhus University

Natera said that this research collaboration and others will help it clinically validate its circulating tumor DNA assay Signatera. 

The new data center will establish a strong foundation for research into the genetic causes of common diseases and how to prevent them.

The projects focus on early treatment of prostate cancer and cataloguing mutations in difficult-to-diagnose diseases, among other things. 

The Copenhagen-based company continues its relationship with Aarhus University Hospital by licensing the prostate cancer biomarkers.

The pipeline offers tools and protocols for analyzing data from reduced representation and whole-genome bisulphite sequencing procedures.

Exiqon announces an exclusive agreement with Aarhus University Hospital to license prostate cancer biomarkers discovered and validated by the hospital.